To assess patient anxiety levels related to COVID-19 and the implications on financial burden among renal cell carcinoma patients, particularly focusing on how the pandemic exacerbates financial toxicity.
Key Findings:
59% of patients were concerned about their savings covering treatment costs.
Only 8% were satisfied with their financial situation, and 25% reported financial stress.
Patients with lower income (<$50,000) were significantly more anxious about financial hardship compared to higher income patients (p < 0.001).
The median COST score was 21.5, indicating varying levels of financial toxicity among patients.
Interpretation:
The COVID-19 pandemic has exacerbated financial toxicity in renal cell carcinoma patients, significantly impacting their anxiety and overall well-being, highlighting the need for targeted interventions.
Limitations:
The survey did not obtain IRB approval as it was conducted by a patient organization, which may limit the generalizability of the findings.
Responses were limited to those who are part of the KCCure membership and may not represent all renal cell carcinoma patients, potentially introducing selection bias.
Conclusion:
The findings highlight the significant financial burdens faced by renal cell carcinoma patients during the COVID-19 pandemic, emphasizing the urgent need for supportive measures to alleviate financial toxicity.
